This site is intended for healthcare professionals

Phase II trials and stem cell therapies

Read time: 10 mins
Last updated:2nd Sep 2020
Published:2nd Sep 2020
What drug therapies on the horizon for NASH? Discover range of treatments currently in phase II trials and the trials that didn’t make it to phase III. Also learn about the potential for stem cell therapies in treating NASH.

There are more than a dozen or so treatments in Phase II trials, including agonists for PPAR and farnesoid X receptors, such as Enanta’s EDP 305.

Enanta plans to start a further Phase III trial ARGON-2 in NASH in early Q2 2020 and start a Phase I study of EDP 297 as a follow up FXR agonist.

Register free for full access to